NASDAQ: ILMN

Illumina's Diversity, Equity, and Inclusion Actions Earn External Recognition and Further Advance Our Culture of Care

Illumina included in the Bloomberg Gender-Equality Index and the Human Rights Campaign Corporate Equality Index
Article

By Dr. Lisa Toppin, Global Head of Diversity and Inclusion

At Illumina, inclusion exists in our purpose, our work, and our practices. We believe diverse perspectives are valued and needed to drive innovation, and that the best ideas and collaboration come from a diverse, inclusive environment where everyone feels safe, respected, and supported.

Let It Grow: A DNA Database for Plants, One Species at a Time

Japan’s Kazusa DNA Research Institute leads an effort to collect plant genomes and make them available to everyone
Article

Plants may be mortal on earth, but on the internet, they can exist in perpetuity.

Illumina's Nonprofit Partner Future Kings Is Cultivating the Next Generation of STEM Leaders

Opening Doors for Students and the Possibilities of a STEM Career
Article

As a middle school math teacher in Woodbridge, Virginia, Dr. Arik King saw firsthand how boys of color trailed their peers in test scores, attendance, and graduation rates—part of an alarming and persistent national trend. Knowing the potential of his students, he designed an after-school program that provided focus and consistent guidance from adult mentors through engaging technology projects.

Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership

Press Release

SAN DIEGO, January 18, 2022 /3BL Media/ -- Illumina Inc. (NASDAQ: ILMN) announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

Illumina Partners With Agendia to Expand Genomic Testing in Breast Cancer Care

Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing and to bring improved insights to patients with breast cancer globally
Press Release

SAN DIEGO, January 12, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) announced a multi-year partnership with Agendia N.V., a world leader in precision oncology for breast cancer, to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina's approach to IVD partnerships in oncology.

Illumina Collaborates With Nashville Biosciences to Accelerate Medicines Development

Collaboration will transform new insights into drug discovery and therapy development through large-scale genomics
Press Release

SAN DIEGO, January 20, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), announced a multi-year agreement to accelerate medicines development through large-scale genomics and the establishment of a preeminent clinico-genomic resource.

Illumina Announces New Innovative Partnerships, Along With New Groundbreaking Technologies at 2022 J.P. Morgan Healthcare Conference

Summary: 

Multiple innovative partnerships with healthcare companies, research institutions, and multiomic developers, along with new groundbreaking technologies, including a new SBS chemistry and long-read capabilities, position Illumina to accelerate genomic adoption and improve human health globally.

Press Release

Multiple innovative partnerships with healthcare companies, research institutions, and multiomic developers, along with new groundbreaking technologies, including a new SBS chemistry and long-read capabilities, position Illumina to accelerate genomic adoption and improve human health globally.

Illumina Enters Co-Development Partnership with SomaLogic to Help Researchers’ Understanding of Biology and Disease

Partnership will Accelerate Next-Generation Sequencing into Fastest-Growing Area of Proteomics Market with Ultra-high Throughput, Ultra-high Plexity Workflow
Press Release

SAN DIEGO, January 6, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan® Proteomics Assay onto Illumina's current and future high throughput next-generation sequencing (NGS) platforms. This partnership accelerates the rapidly growing high throughput sector of the proteomics market.

Illumina Donates Over $14 Million to Local Communities and Volunteers More Than 6,000 Hours in 2021

Multimedia with summary

As we wrap up 2021, we would like to thank our employees for giving back to our communities around the world. Despite the continued challenges of the pandemic, you continued to show up with participation in our giving and volunteering program.

The Illumina Cares program provides giving opportunities and encourages employees to volunteer in their local communities. We match employee donations, offer paid volunteer time off, and support a volunteer rewards program to earn giving dollars for each hour of volunteer work.

Pages

Subscribe to NASDAQ: ILMN